Sodium arsenite-induced abnormalities in expressions of Caveolin-1, eNOS, IKKβ, and COX-2 in SV-40 immortalized human uroepithelial cells and in urothelial carcinomas

Toxicology in Vitro

Volumn 26, Issue 7, 2012, Pages 1098-1105

  Liu, Xuan Ping ^a   Huang, Ya Chun ^a   Hung, Wen Chun ^b,c   Chen, Wan Tzu ^d   Yu, Hsin Su ^d,e   Chai, Chee Yin ^a,b,d,e  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Sodium arsenite; SV HUC 1 cells; Uroepithelial cells; Urothelial carcinoma

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ARSENITE SODIUM; CAVEOLIN 1; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; I KAPPA B KINASE BETA;

AGED; ARTICLE; BLACKFOOT DISEASE; BLADDER CARCINOGENESIS; CANCER CELL CULTURE; CARCINOGENIC ACTIVITY; CELL IMMORTALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENDEMIC DISEASE; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; MALE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSITIONAL CELL CARCINOMA; UPREGULATION; WESTERN BLOTTING;

ARSENITES; CARCINOGENS; CARCINOMA, TRANSITIONAL CELL; CAVEOLIN 1; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, VIRAL; CYCLOOXYGENASE 2; HUMANS; I-KAPPA B KINASE; NITRIC OXIDE SYNTHASE TYPE III; SIGNAL TRANSDUCTION; SIMIAN VIRUS 40; SODIUM COMPOUNDS; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 84866013261     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2012.07.003     Document Type: Article

References (58)

1. Bates M.N., Rey O.A., Biggs M.L., Hopenhayn C., Moore L.E., Kalman D., Steinmaus C., Smith A.H. Case-control study of bladder cancer and exposure to arsenic in Argentina. Am. J. Epidemiol. 2004, 159:381-389.
2. Biscardi J.S., Maa M.C., Tice D.A., Cox M.E., Leu T.H., Parsons S.J. C-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J. Biol. Chem. 1999, 274:8335-8343.
3. Boland G.P., Butt I.S., Prasad R., Knox W.F., Bundred N.J. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br. J. Cancer 2004, 90:423-429.
4. Campbell L., Gumbleton M., Griffiths D.F. Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Br. J. Cancer 2003, 89:1909-1913.
5. Chang Y.W., Jakobi R., McGinty A., Foschi M., Dunn M.J., Sorokin A. Cyclooxygenase 2 promotes cell survival by stimulation of dynein light chain expression and inhibition of neuronal nitric oxide synthase activity. Mol. Cell. Biol. 2000, 20:8571-8579.
6. Chen C.J., Chuang Y.C., Lin T.M., Wu H.Y. Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res. 1985, 45:5895-5899.
7. Chen C.H., Chiou H.Y., Hsueh Y.M., Chen C.J., Yu H.J., Pu Y.S. Clinicopathological characteristics and survival outcome of arsenic related bladder cancer in Taiwan. J. Urol. 2009, 181:547-552.
8. Cheng T.J., Ke D.S., Guo H.R. The association between arsenic exposure from drinking water and cerebrovascular disease mortality in Taiwan. Water Res. 2010, 44:5770-5776.
9. Chiang H.S., Guo H.R., Hong C.L., Lin S.M., Lee E.F. The incidence of bladder cancer in the black foot disease endemic area in Taiwan. Br. J. Urol. 1993, 71:274-278.
10. Chiou H.Y., Chiou S.T., Hsu Y.H., Chou Y.L., Tseng C.H., Wei M.L., Chen C.J. Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan. Am. J. Epidemiol. 2001, 153:411-418.
11. Chou Y., Tsai C.H., Ueng K.C., Tian T.Y., Chen S.C., Yeh H.I. Endothelial gap junctions are down-regulated by arsenic trioxide. Eur. J. Pharmacol. 2007, 569:29-36.
12. Cohen S.M., Ohnishi T., Arnold L.L., Le X.C. Arsenic-induced bladder cancer in an animal model. Toxicol. Appl. Pharmacol. 2007, 222:258-263.
13. Ding J., Li J., Xue C., Wu K., Ouyang W., Zhang D., Yan Y., Huang C. Cyclooxygenase-2 induction by arsenite is through a nuclear factor of activated T-cell-dependent pathway and plays an antiapoptotic role in Beas-2B cells. J. Biol. Chem. 2006, 281:24405-24413.
14. Drab M., Verkade P., Elger M., Kasper M., Lohn M., Lauterbach B., Menne J., Lindschau C., Mende F., Luft F.C., Schedl A., Haller H., Kurzchalia T.V. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001, 293:2449-2452.
15. Eble J.N., Sauter G., Epstein J.I., Sesterhenn I.A. Pathology and genetics of tumors of the urinary system and male genital organs 2004, IARC, Lyon.
16. Fong A., Garcia E., Gwynn L., Lisanti M.P., Fazzari M.J., Li M. Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation. Am. J. Clin. Pathol. 2003, 120:93-100.
17. Glauert H.P., Calfee-Mason K., Li Y., Nilakantan V., Twaroski M.L., Tharappel J., Spear B.T. The role of NF-kappaB in PPARalpha-mediated hepatocarcinogenesis. PPAR Res. 2008, 2008:286249.
18. Hall D., Beattie D., Grossman S., Campbell C. Multisystem failure of the arsenic-poisoned patient. Dimens Crit. Care Nurs. 1991, 10:151-159.
19. Hu M.C., Hung M.C. Role of IkappaB kinase in tumorigenesis. Future Oncol. 2005, 1:67-78.
20. Huang Y.C., Hung W.C., Chen W.T., Yu H.S., Chai C.Y. Sodium arsenite-induced DAPK promoter hypermethylation and autophagy via ERK1/2 phosphorylation in human uroepithelial cells. Chem. Biol. Interact. 2009, 181:254-262.
21. Huang Y.K., Huang Y.L., Hsueh Y.M., Yang M.H., Wu M.M., Chen S.Y., Hsu L.I., Chen C.J. Arsenic exposure, urinary arsenic speciation, and the incidence of urothelial carcinoma: a twelve-year follow-up study. Cancer Causes Control 2008, 19:829-839.
22. Hussain S.P., He P., Subleski J., Hofseth L.J., Trivers G.E., Mechanic L., Hofseth A.B., Bernard M., Schwank J., Nguyen G., Mathe E., Djurickovic D., Haines D., Weiss J., Back T., et al. Nitric oxide is a key component in inflammation-accelerated tumorigenesis. Cancer Res. 2008, 68:7130-7136.
23. Iesan C.M., Capat C., Ruta F., Udrea I. Evaluation of a novel hybrid inorganic/organic polymer type material in the arsenic removal process from drinking water. Water Res. 2008, 42:4327-4333.
24. Ju H., Zou R., Venema V.J., Venema R.C. Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. J. Biol. Chem. 1997, 272:18522-18525.
25. Kennedy R.A., Kemp T.J., Sugden P.H., Clerk A. Using U0126 to dissect the role of the extracellular signal-regulated kinase 1/2 (ERK1/2) cascade in the regulation of gene expression by endothelin-1 in cardiac myocytes. J. Mol. Cell Cardiol. 2006, 41:236-247.
26. Kradin R., Matsubara O., Mark E.J. Endothelial nitric oxide synthase expression in pulmonary capillary hemangiomatosis. Exp. Mol. Pathol. 2005, 79:194-197.
27. Kurttio P., Pukkala E., Kahelin H., Auvinen A., Pekkanen J. Arsenic concentrations in well water and risk of bladder and kidney cancer in Finland. Environ. Health Perspect. 1999, 107:705-710.
28. Le X., Wei D., Huang S., Lancaster J.R., Xie K. Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its up-regulation of protumor factors. Proc. Natl. Acad. Sci. USA 2005, 102:8758-8763.
29. Lee T.C., Ho I.C. Differential cytotoxic effects of arsenic on human and animal cells. Environ. Health Perspect. 1994, 102(Suppl 3):101-105.
30. Lisanti M.P., Scherer P.E., Vidugiriene J., Tang Z., Hermanowski-Vosatka A., Tu Y.H., Cook R.F., Sargiacomo M. Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source. implications for human disease. J. Cell Biol. 1994, 126:111-126.
31. Lu Y., Wahl L.M. Oxidative stress augments the production of matrix metalloproteinase-1, cyclooxygenase-2, and prostaglandin E2 through enhancement of NF-kappa B activity in lipopolysaccharide-activated human primary monocytes. J. Immunol. 2005, 175:5423-5429.
32. Lv P.P., Fan Y., Chen W.L., Shen Y.L., Zhu L., Wang L.L., Chen Y.Y. COX-2 inhibitor nimesulide protects rat heart against oxidative stress by improving endothelial function and enhancing NO production. Sheng Li Xue Bao 2007, 59:674-680.
33. Ouyang W., Zhang D., Ma Q., Li J., Huang C. Cyclooxygenase-2 induction by arsenite through the IKKbeta/NFkappaB pathway exerts an antiapoptotic effect in mouse epidermal Cl41 cells. Environ. Health Perspect. 2007, 115:513-518.
34. Peng J.P., Su C.Y., Chang H.C., Chai C.Y., Hung W.C. Overexpression of cyclo-oxygenase 2 in squamous cell carcinoma of the hypopharynx. Hum. Pathol. 2002, 33:100-104.
35. Pi J., Horiguchi S., Sun Y., Nikaido M., Shimojo N., Hayashi T., Yamauchi H., Itoh K., Yamamoto M., Sun G., Waalkes M.P., Kumagai Y. A potential mechanism for the impairment of nitric oxide formation caused by prolonged oral exposure to arsenate in rabbits. Free Radic. Biol. Med. 2003, 35:102-113.
36. Rajjayabun P.H., Garg S., Durkan G.C., Charlton R., Robinson M.C., Mellon J.K. Caveolin-1 expression is associated with high-grade bladder cancer. Urology 2001, 58:811-814.
37. Razani B., Engelman J.A., Wang X.B., Schubert W., Zhang X.L., Marks C.B., Macaluso F., Russell R.G., Li M., Pestell R.G., Di Vizio D., Hou H., Kneitz B., Lagaud G., Christ G.J., et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J. Biol. Chem. 2001, 276:38121-38138.
38. Schmid J.A., Birbach A. IkappaB kinase beta (IKKbeta/IKK2/IKBKB)-a key molecule in signaling to the transcription factor NF-kappaB. Cytokine Growth Factor Rev. 2008, 19:157-165.
39. Shatz M., Liscovitch M. Caveolin-1: a tumor-promoting role in human cancer. Int. J. Radiat. Biol. 2008, 84:177-189.
40. Shibata A., Ohneseit P.F., Tsai Y.C., Spruck C.H., Nichols P.W., Chiang H.S., Lai M.K., Jones P.A. Mutational spectrum in the p53 gene in bladder tumors from the endemic area of black foot disease in Taiwan. Carcinogenesis 1994, 15:1085-1087.
41. Shochina M., Fellig Y., Sughayer M., Pizov G., Vitner K., Podeh D., Hochberg A., Ariel I. Nitric oxide synthase immunoreactivity in human bladder carcinoma. Mol. Pathol. 2001, 54:248-252.
42. Solt L.A., May M.J. The IkappaB kinase complex: master regulator of NF-kappaB signaling. Immunol. Res. 2008, 42:3-18.
43. Tan L.B., Chen K.T., Guo H.R. Clinical and epidemiological features of patients with genitourinary tract tumour in a blackfoot disease endemic area of Taiwan. BJU Int. 2008, 102:48-54.
44. Tsai S.H., Liang Y.C., Chen L., Ho F.M., Hsieh M.S., Lin J.K. Arsenite stimulates cyclooxygenase-2 expression through activating IkappaB kinase and nuclear factor kappaB in primary and ECV304 endothelial cells. J. Cell. Biochem. 2002, 84:750-758.
45. Tseng W.P., Chu H.M., How S.W., Fong J.M., Lin C.S., Yeh S. Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J. Natl Cancer Inst. 1968, 40:453-463.
46. Tsou T.C., Tsai F.Y., Hsieh Y.W., Li L.A., Yeh S.C., Chang L.W. Arsenite induces endothelial cytotoxicity by down-regulation of vascular endothelial nitric oxide synthase. Toxicol. Appl. Pharmacol. 2005, 208:277-284.
47. Waalkes M.P., Liu J., Chen H., Xie Y., Achanzar W.E., Zhou Y.S., Cheng M.L., Diwan B.A. Estrogen signaling in livers of male mice with hepatocellular carcinoma induced by exposure to arsenic in utero. J. Natl Cancer Inst. 2004, 96:466-474.
48. Wild P.J., Kunz-Schughart L.A., Stoehr R., Burger M., Blaszyk H., Simon R., Gasser T., Mihatsch M., Sauter G., Hartmann A. High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. Int. J. Oncol. 2005, 27:385-391.
49. Williams T.M., Hassan G.S., Li J., Cohen A.W., Medina F., Frank P.G., Pestell R.G., Di Vizio D., Loda M., Lisanti M.P. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J. Biol. Chem. 2005, 280:25134-25145.
50. Williams T.M., Lisanti M.P. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am. J. Physiol. Cell Physiol. 2005, 288:C494-506.
51. Xu W., Liu L.Z., Loizidou M., Ahmed M., Charles I.G. The role of nitric oxide in cancer. Cell Res. 2002, 12:311-320.
52. Yamada E. The fine structure of the gall bladder epithelium of the mouse. J. Biophys. Biochem. Cytol. 1955, 1:445-458.
53. Zandi E., Chen Y., Karin M. Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: discrimination between free and NF-kappaB-bound substrate. Science 1998, 281:1360-1363.
54. Zhang Q., Church J.E., Jagnandan D., Catravas J.D., Sessa W.C., Fulton D. Functional relevance of Golgi- and plasma membrane-localized endothelial NO synthase in reconstituted endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1015-1021.
55. Zhang W., Liu H.T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002, 12:9-18.
56. Zheng Y., Lim E.J., Wang L., Smart E.J., Toborek M., Hennig B. Role of caveolin-1 in EGCG-mediated protection against linoleic-acid-induced endothelial cell activation. J. Nutr. Biochem. 2009, 20:202-209.
57. Zhu J., Song X., Lin H.P., Young D.C., Yan S., Marquez V.E., Chen C.S. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J. Natl Cancer Inst. 2002, 94:1745-1757.
58. Zulli A., Buxton B.F., Black M.J., Ming Z., Cameron A., Hare D.L. The immunoquantification of caveolin-1 and eNOS in human and rabbit diseased blood vessels. J. Histochem. Cytochem. 2006, 54:151-159.